Webcasts
"The fear of what lay ahead"
Raising children with Erythropoietic Protoporphyria (EPP) is a traumatising experience, one which few parents are able to express or understand. Watch video...
"Separate yourself from the pain"
Adrian was diagnosed with the genetic disease Erythropoietic Protoporphyria (EPP) when he was 5. Exposure to light causes him excruciating pain. Watch video...
Absolute light intolerance: Erythropoietic protoporphyria (EPP)
Erythropoietic protoporphyria (EPP) is a rare and severe UV/light related skin disorder. Watch video...
Clinuvel, improving quality of life
Afamelanotide holds promise as a preventative treatment, improving quality of life for patients with advanced stage bile duct cancer, undergoing Photodynamic Therapy (PDT). Watch video...
Clinuvel's regulatory strategy
Clinuvel's CSO, Dr Hank Agersborg, discusses the company's regulatory strategy following the announcement of a confirmatory Phase III EPP study. Listen to podcast...
Light and UV in Australia
In Australia, we understand, appreciate and respect light and UV. Watch video...
The evolution of pharmaceutical development
CSO, Dr Hank Agersborg, discusses drug development at Clinuvel. Listen to podcast...
Final year of filing MAA
Clinuvel's CSO, Dr Hank Agersborg, on the final year of drug filing. Listen to podcast...
"the golden age?"
Clinuvel directors discuss the progress of Clinuvel's clinical program with afamelanotide. Watch video...
"Clinical and regulatory goals"
Senior management in regulatory and clinical research discuss the development of afamelanotide. Watch video...
"Where no one has gone before"
Clinuvel's non-executive director Jack Wood discusses commercialization strategies. Watch video...
